Immunotherapy for Renal Cell Carcinoma
2010

Immunotherapy for Renal Cell Carcinoma

publication Evidence: moderate

Author Information

Author(s): M. Itsumi, Katsunori Tatsugami

Primary Institution: Department of Urology, Graduate School of Medical Sciences, Kyushu University

Hypothesis

Immunotherapy can improve outcomes for patients with renal cell carcinoma (RCC) despite the disease's resistance to traditional treatments.

Conclusion

Immunotherapy shows promise in treating RCC, but the response rates remain low and long-term improvements are rare.

Supporting Evidence

  • Immunotherapy has shown anti-tumor activity in RCC patients.
  • Only 10%-20% of patients respond positively to cytokine treatments.
  • Recent studies indicate the importance of immune regulation in RCC treatment.

Takeaway

Doctors are trying to use the body's immune system to fight kidney cancer, but it doesn't work for everyone.

Methodology

The review discusses various immunotherapy approaches and their effectiveness based on clinical trials.

Limitations

The review highlights the low response rates and challenges in evaluating the efficacy of immunotherapy compared to other treatments.

Digital Object Identifier (DOI)

10.1155/2010/284581

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication